TGNA:FRA
Transgene SA
€0.68
arrow_downward
-1.88%(-0.013) 1H
5 Okt, 8:11:52 PG GMT+2 · EUR
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk TGNA...
Buka
€0.68
Tinggi
€0.68
Rendah
€0.68
Permodalan Pasaran
201.40J
Purata volum
0.00
Volum
0.00
tgi 52 mgu
€1.48
rdh 52 mgu
€0.60
EPS
-€0.17
Bilangan pekerja
160
Buka
€0.68
Tinggi
€0.68
Rendah
€0.68
Permodalan Pasaran
201.40J
Purata volum
0.00
Volum
0.00
tgi 52 mgu
€1.48
rdh 52 mgu
€0.60
EPS
-€0.17
Bilangan pekerja
160
Cerita berita
Daripada sumber web dan rakan kongsi berita
TipRanks
·
1 jam lalu
Transgene to Showcase Systemic Oncolytic Virus Data at SITC 2026
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Perihal Transgene SA